Nice find. When I look at the possibilities ahead, I am getting more and more convinced we should go it alone for Phase 3 and subsequently license the drug. At close to $1B MC, we can afford to raise for a $200M trial. It appears we have some strong support from a few funds who continue to buy up at these levels and would happily open up the purse strings for a potential 5-Disallowed from here.
- Forums
- ASX - By Stock
- price target
Nice find. When I look at the possibilities ahead, I am getting...
Featured News
Add OPT (ASX) to my watchlist
|
|||||
Last
$1.02 |
Change
-0.035(3.33%) |
Mkt cap ! $1.249B |
Open | High | Low | Value | Volume |
$1.06 | $1.06 | $1.01 | $2.020M | 1.977M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 989 | $1.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.03 | 23618 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 989 | 1.010 |
3 | 5438 | 1.005 |
25 | 125596 | 1.000 |
4 | 40393 | 0.995 |
2 | 11000 | 0.990 |
Price($) | Vol. | No. |
---|---|---|
1.025 | 23618 | 1 |
1.030 | 37868 | 3 |
1.035 | 160 | 1 |
1.040 | 3847 | 2 |
1.050 | 53712 | 11 |
Last trade - 16.10pm 12/02/2025 (20 minute delay) ? |
Featured News
OPT (ASX) Chart |
The Watchlist
AII
ALMONTY INDUSTRIES INC.
Matthias Greiffenberger, Analyst, GBC Investment Research
Matthias Greiffenberger
Analyst, GBC Investment Research
Previous Video
Next Video
SPONSORED BY The Market Online